Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.

Cancer Manag Res · 2019 · PMC6519338 · PMID 31191001

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Study 19, SOLO2 and SOLO1 are all randomized, double-blind, placebo-controlled phase II/III studies of olaparib monotherapy that are highly significant (Study 19: NCT00753545 , SOLO2: NCT01874353 , and SOLO1: NCT01844986 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.